Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.

Tools

Pettitt, A.R., Matutes, E. M. and Oscier, D. G., 2006. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia, 20, pp. 1441-1445.

Full text not available from this repository.

Official URL: http://www.nature.com/leu/journal/v20/n8/abs/24042...

DOI: 10.1038/sj.leu.2404265

Abstract

A letter to the editor is presented in response to an article about the feasibility and efficacy of alemtuzumab combined with methylprednisolone as a therapeutic regimen in chronic lymphocytic leukemia patients with p53 defects.

Item Type:Article
ISSN:0887-6924
Subjects:Technology > Medicine and Health
Group:School of Health and Social Care > Centre for Postgraduate Medical Research and Education
ID Code:6274
Deposited By:INVALID USER
Deposited On:02 Nov 2008 15:56
Last Modified:07 Mar 2013 14:51
Repository Staff Only -
BU Staff Only -
Help Guide - Editing Your Items in BURO